FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:125-134 January 11, 2007 Number 2 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Editorial by Brugarolas, J. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

ABSTRACT

Background We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.

Methods From November 2003 to March 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to standard therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo. The primary end point was overall survival. A single planned analysis of progression-free survival in January 2005 showed a statistically significant benefit of sorafenib over placebo. Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.

Results At the January 2005 cutoff, the median progression-free survival was 5.5 months in the sorafenib group and 2.8 months in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55; P<0.01). The first interim analysis of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94; P=0.02), although this benefit was not statistically significant according to the O'Brien–Fleming threshold. Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo (P<0.001). Diarrhea, rash, fatigue, and hand–foot skin reactions were the most common adverse events associated with sorafenib. Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.

Conclusions As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is associated with increased toxic effects. (ClinicalTrials.gov number, NCT00073307 [ClinicalTrials.gov] .)

Source Information

From Institut Gustave Roussy, Villejuif, France (B.E.); Cambridge Research Institute, Cambridge, United Kingdom (T.E.); University of Chicago, Chicago (W.M.S., A.A.D.); Military School of Medicine, Warsaw, Poland (C.S.); Hôpital Européen Georges Pompidou, Paris (S.O.); Klinikum Grosshadern der Ludwig Maximilians Universität, Munich, Germany (M. Siebels); Centre Léon Bérard, Lyon, France (S.N.); Institut Claudius Regaud, Toulouse, France (C.C.); Wojewodzka Przychodnia Onkolog, Gdansk, Poland (E.S.); Centre René Gauducheau, Saint-Herblain, France (F.R.); Centrum Onkologii, Warsaw, Poland (T.D.); Baylor Charles A. Sammons Cancer Center, Dallas (T.E.H.); Royal Marsden Hospital, Surrey, United Kingdom (M.G.); Onyx Pharmaceuticals, Emeryville, CA (S.F.); Bayer Pharmaceuticals, West Haven, CT (B.S., M. Shan, R.S.); and Cleveland Clinic Taussig Cancer Center, Cleveland (R.M.B.).

Address reprint requests to Dr. Escudier at the Department of Medicine, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif, France, or at escudier{at}igr.fr.

Full Text of this Article

This article has been cited by other articles:

• Winn, S. K., Ellis, S., Savage, P., Sampson, S., Marsh, J. E. (2008). Biopsy proven acute interstitial nephritis associated with the tyrosine kinase inhibitor sunitinib: a class effect?. Nephrol Dial Transplant 0: gfn625v1-gfn625 [Abstract] [Full Text]  
• Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S.-S., Archer, L., Atkins, J. N., Picus, J., Czaykowski, P., Dutcher, J., Small, E. J. (2008). Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206. JCO 26: 5422-5428 [Abstract] [Full Text]  
• Hu-Lowe, D. D., Zou, H. Y., Grazzini, M. L., Hallin, M. E., Wickman, G. R., Amundson, K., Chen, J. H., Rewolinski, D. A., Yamazaki, S., Wu, E. Y., McTigue, M. A., Murray, B. W., Kania, R. S., O'Connor, P., Shalinsky, D. R., Bender, S. L. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clin. Cancer Res. 14: 7272-7283 [Abstract] [Full Text]  
• Schmidinger, M., Zielinski, C. C., Vogl, U. M., Bojic, A., Bojic, M., Schukro, C., Ruhsam, M., Hejna, M., Schmidinger, H. (2008). Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma. JCO 26: 5204-5212 [Abstract] [Full Text]  
• Lacouture, M. E., Reilly, L. M., Gerami, P., Guitart, J. (2008). Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19: 1955-1961 [Abstract] [Full Text]  
• Loriot, Y., Boudou-Rouquette, P., Billemont, B., Ropert, S., Goldwasser, F. (2008). Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib. Ann Oncol 19: 1975-1975 [Full Text]  
• Sleijfer, S., van der Graaf, W. T.A., Blay, J.-Y. (2008). Angiogenesis Inhibition in Non-GIST Soft Tissue Sarcomas. The Oncologist 13: 1193-1200 [Abstract] [Full Text]  
• Eisen, T., Oudard, S., Szczylik, C., Gravis, G., Heinzer, H., Middleton, R., Cihon, F., Anderson, S., Shah, S., Bukowski, R., Escudier, B., for the TARGET Study Group, (2008). Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial. JNCI J Natl Cancer Inst 100: 1454-1463 [Abstract] [Full Text]  
• Ellis, L. M., Hicklin, D. J. (2008). Pathways Mediating Resistance to Vascular Endothelial Growth Factor-Targeted Therapy. Clin. Cancer Res. 14: 6371-6375 [Abstract] [Full Text]  
• Gupta-Abramson, V., Troxel, A. B., Nellore, A., Puttaswamy, K., Redlinger, M., Ransone, K., Mandel, S. J., Flaherty, K. T., Loevner, L. A., O'Dwyer, P. J., Brose, M. S. (2008). Phase II Trial of Sorafenib in Advanced Thyroid Cancer. JCO 26: 4714-4719 [Abstract] [Full Text]  
• Hahn, O. M., Yang, C., Medved, M., Karczmar, G., Kistner, E., Karrison, T., Manchen, E., Mitchell, M., Ratain, M. J., Stadler, W. M. (2008). Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma. JCO 26: 4572-4578 [Abstract] [Full Text]  
• Schneider, B. P., Wang, M., Radovich, M., Sledge, G. W., Badve, S., Thor, A., Flockhart, D. A., Hancock, B., Davidson, N., Gralow, J., Dickler, M., Perez, E. A., Cobleigh, M., Shenkier, T., Edgerton, S., Miller, K. D. (2008). Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100. JCO 26: 4672-4678 [Abstract] [Full Text]  
• Ng, C. S., Wood, C. G., Silverman, P. M., Tannir, N. M., Tamboli, P., Sandler, C. M. (2008). Renal Cell Carcinoma: Diagnosis, Staging, and Surveillance. Am. J. Roentgenol. 191: 1220-1232 [Abstract] [Full Text]  
• Wilhelm, S. M., Adnane, L., Newell, P., Villanueva, A., Llovet, J. M., Lynch, M. (2008). Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Molecular Cancer Therapeutics 7: 3129-3140 [Abstract] [Full Text]  
• Stein, W. D., Yang, J., Bates, S. E., Fojo, T. (2008). Bevacizumab Reduces the Growth Rate Constants of Renal Carcinomas: A Novel Algorithm Suggests Early Discontinuation of Bevacizumab Resulted in a Lack of Survival Advantage. The Oncologist 13: 1055-1062 [Abstract] [Full Text]  
• Hutson, T. E., Figlin, R. A., Kuhn, J. G., Motzer, R. J. (2008). Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies. The Oncologist 13: 1084-1096 [Abstract] [Full Text]  
• Willmann, J. K., Lutz, A. M., Paulmurugan, R., Patel, M. R., Chu, P., Rosenberg, J., Gambhir, S. S. (2008). Dual-targeted Contrast Agent for US Assessment of Tumor Angiogenesis in Vivo. Radiology 248: 936-944 [Abstract] [Full Text]  
• Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., Asada, M. (2008). Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase. Clin. Cancer Res. 14: 5459-5465 [Abstract] [Full Text]  
• Jiang, Z., Chu, P. G., Woda, B. A., Liu, Q., Balaji, K.C., Rock, K. L., Wu, C.-L. (2008). Combination of Quantitative IMP3 and Tumor Stage: A New System to Predict Metastasis for Patients with Localized Renal Cell Carcinomas. Clin. Cancer Res. 14: 5579-5584 [Abstract] [Full Text]  
• Lacouture, M. E., Wu, S., Robert, C., Atkins, M. B., Kong, H. H., Guitart, J., Garbe, C., Hauschild, A., Puzanov, I., Alexandrescu, D. T., Anderson, R. T., Wood, L., Dutcher, J. P. (2008). Evolving Strategies for the Management of Hand-Foot Skin Reaction Associated with the Multitargeted Kinase Inhibitors Sorafenib and Sunitinib. The Oncologist 13: 1001-1011 [Abstract] [Full Text]  
• Salama, J. K., Chmura, S. J., Mehta, N., Yenice, K. M., Stadler, W. M., Vokes, E. E., Haraf, D. J., Hellman, S., Weichselbaum, R. R. (2008). An Initial Report of a Radiation Dose-Escalation Trial in Patients with One to Five Sites of Metastatic Disease. Clin. Cancer Res. 14: 5255-5259 [Abstract] [Full Text]  
• Crispen, P. L., Sheinin, Y., Roth, T. J., Lohse, C. M., Kuntz, S. M., Frigola, X., Thompson, R. H., Boorjian, S. A., Dong, H., Leibovich, B. C., Blute, M. L., Kwon, E. D. (2008). Tumor Cell and Tumor Vasculature Expression of B7-H3 Predict Survival in Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 14: 5150-5157 [Abstract] [Full Text]  
• Cannistra, S. A. (2008). Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies. JCO 26: 3665-3667 [Full Text]  
• Azad, N. S., Posadas, E. M., Kwitkowski, V. E., Steinberg, S. M., Jain, L., Annunziata, C. M., Minasian, L., Sarosy, G., Kotz, H. L., Premkumar, A., Cao, L., McNally, D., Chow, C., Chen, H. X., Wright, J. J., Figg, W. D., Kohn, E. C. (2008). Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity. JCO 26: 3709-3714 [Abstract] [Full Text]  
• Dodd, L. E., Korn, E. L., Freidlin, B., Jaffe, C. C., Rubinstein, L. V., Dancey, J., Mooney, M. M. (2008). Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?. JCO 26: 3791-3796 [Abstract] [Full Text]  
• Carden, C. P., Larkin, J. M.G., Rosenthal, M. A. (2008). What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 10: 624-630 [Abstract] [Full Text]  
• Ding, Q., Huo, L., Yang, J.-Y., Xia, W., Wei, Y., Liao, Y., Chang, C.-J., Yang, Y., Lai, C.-C., Lee, D.-F., Yen, C.-J., Chen, Y.-J. R., Hsu, J.-M., Kuo, H.-P., Lin, C.-Y., Tsai, F.-J., Li, L.-Y., Tsai, C.-H., Hung, M.-C. (2008). Down-regulation of Myeloid Cell Leukemia-1 through Inhibiting Erk/Pin 1 Pathway by Sorafenib Facilitates Chemosensitization in Breast Cancer. Cancer Res. 68: 6109-6117 [Abstract] [Full Text]  
• Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19: 1387-1392 [Abstract] [Full Text]  
• Negrier, S. (2008). Temsirolimus in metastatic renal cell carcinoma. Ann Oncol 19: 1369-1370 [Full Text]  
• Nickerson, M. L., Jaeger, E., Shi, Y., Durocher, J. A., Mahurkar, S., Zaridze, D., Matveev, V., Janout, V., Kollarova, H., Bencko, V., Navratilova, M., Szeszenia-Dabrowska, N., Mates, D., Mukeria, A., Holcatova, I., Schmidt, L. S., Toro, J. R., Karami, S., Hung, R., Gerard, G. F., Linehan, W. M., Merino, M., Zbar, B., Boffetta, P., Brennan, P., Rothman, N., Chow, W.-H., Waldman, F. M., Moore, L. E. (2008). Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors. Clin. Cancer Res. 14: 4726-4734 [Abstract] [Full Text]  
• Flaherty, K. T., Schiller, J., Schuchter, L. M., Liu, G., Tuveson, D. A., Redlinger, M., Lathia, C., Xia, C., Petrenciuc, O., Hingorani, S. R., Jacobetz, M. A., Van Belle, P. A., Elder, D., Brose, M. S., Weber, B. L., Albertini, M. R., O'Dwyer, P. J. (2008). A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel. Clin. Cancer Res. 14: 4836-4842 [Abstract] [Full Text]  
• Henderson, Y. C., Ahn, S.-H., Kang, Y., Clayman, G. L. (2008). Sorafenib Potently Inhibits Papillary Thyroid Carcinomas Harboring RET/PTC1 Rearrangement. Clin. Cancer Res. 14: 4908-4914 [Abstract] [Full Text]  
• Dal Lago, L., D'Hondt, V., Awada, A. (2008). Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. The Oncologist 13: 845-858 [Abstract] [Full Text]  
• Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., Schwartz, M., Porta, C., Zeuzem, S., Bolondi, L., Greten, T. F., Galle, P. R., Seitz, J.-F., Borbath, I., Haussinger, D., Giannaris, T., Shan, M., Moscovici, M., Voliotis, D., Bruix, J., the SHARP Investigators Study Group, (2008). Sorafenib in Advanced Hepatocellular Carcinoma. NEJM 359: 378-390 [Abstract] [Full Text]  
• Sleijfer, S., Wiemer, E. (2008). In Reply. JCO 26: 3652-3653 [Full Text]  
• Strumberg, D. (2008). Efficacy of Sunitinib and Sorafenib in Non-Clear Cell Renal Cell Carcinoma: Results From Expanded Access Studies. JCO 26: 3469-3471 [Full Text]  
• Choueiri, T. K., Bukowski, R. M., Escudier, B. (2008). In Reply. JCO 26: 3471-3471 [Full Text]  
• Ammoun, S., Flaiz, C., Ristic, N., Schuldt, J., Hanemann, C. O. (2008). Dissecting and Targeting the Growth Factor-Dependent and Growth Factor-Independent Extracellular Signal-Regulated Kinase Pathway in Human Schwannoma. Cancer Res. 68: 5236-5245 [Abstract] [Full Text]  
• Autier, J., Escudier, B., Wechsler, J., Spatz, A., Robert, C. (2008). Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor. Arch Dermatol 144: 886-892 [Abstract] [Full Text]  
• Sabir, A., Schor-Bardach, R., Wilcox, C. J., Rahmanuddin, S., Atkins, M. B., Kruskal, J. B., Signoretti, S., Raptopoulos, V. D., Goldberg, S. N. (2008). Perfusion MDCT Enables Early Detection of Therapeutic Response to Antiangiogenic Therapy. Am. J. Roentgenol. 191: 133-139 [Abstract] [Full Text]  
• Trotta, F., Apolone, G., Garattini, S., Tafuri, G. (2008). Stopping a trial early in oncology: for patients or for industry?. Ann Oncol 19: 1347-1353 [Abstract] [Full Text]  
• Chen, M. H., Kerkela, R., Force, T. (2008). Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics. Circulation 118: 84-95 [Full Text]  
• Michaelson, M. D., Iliopoulos, O., McDermott, D. F., McGovern, F. J., Harisinghani, M. G., Oliva, E. (2008). Case 17-2008 -- A 63-Year-Old Man with Metastatic Renal-Cell Carcinoma. NEJM 358: 2389-2396 [Full Text]  
• Ravaud, A., Hawkins, R., Gardner, J. P., von der Maase, H., Zantl, N., Harper, P., Rolland, F., Audhuy, B., Machiels, J.-P., Petavy, F., Gore, M., Schoffski, P., El-Hariry, I. (2008). Lapatinib Versus Hormone Therapy in Patients With Advanced Renal Cell Carcinoma: A Randomized Phase III Clinical Trial. JCO 26: 2285-2291 [Abstract] [Full Text]  
• Kerbel, R. S. (2008). Tumor Angiogenesis. NEJM 358: 2039-2049 [Full Text]  
• Bukowski, R. M. (2008). How I Treat Renal Cell Carcinoma. J Oncol Pract 4: 150-152 [Full Text]  
• Schlom, J., Gulley, J. L., Arlen, P. M. (2008). Paradigm Shifts in Cancer Vaccine Therapy. Exp. Biol. Med. 233: 522-534 [Abstract] [Full Text]  
• Ellis, L. M (2008). Resistance to Anti-VEGF Therapy. aacredbook 2008: 203-207 [Abstract] [Full Text]  
• Laurie, S. A., Gauthier, I., Arnold, A., Shepherd, F. A., Ellis, P. M., Chen, E., Goss, G., Powers, J., Walsh, W., Tu, D., Robertson, J., Puchalski, T. A., Seymour, L. (2008). Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. JCO 26: 1871-1878 [Abstract] [Full Text]  
• Fleming, T. R, Sharples, K., McCall, J., Moore, A., Rodgers, A., Stewart, R. (2008). Maintaining confidentiality of interim data to enhance trial integrity and credibility. Clin Trials 5: 157-167 [Abstract]  
• Brown, E. N., Herrington, J. D. (2008). Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment. Journal of Pharmacy Practice 21: 126-137 [Abstract]  
• Frei, B. L., Soefje, S. A. (2008). A Review of the Cardiovascular Effects of Oncology Agents. Journal of Pharmacy Practice 21: 146-158 [Abstract]  
• Chi, K. N., Ellard, S. L., Hotte, S. J., Czaykowski, P., Moore, M., Ruether, J. D., Schell, A. J., Taylor, S., Hansen, C., Gauthier, I., Walsh, W., Seymour, L. (2008). A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 19: 746-751 [Abstract] [Full Text]  
• Sarker, D., Molife, R., Evans, T.R. J., Hardie, M., Marriott, C., Butzberger-Zimmerli, P., Morrison, R., Fox, J. A., Heise, C., Louie, S., Aziz, N., Garzon, F., Michelson, G., Judson, I. R., Jadayel, D., Braendle, E., de Bono, J. S. (2008). A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors. Clin. Cancer Res. 14: 2075-2081 [Abstract] [Full Text]  
• Moreno-Vinasco, L., Gomberg-Maitland, M., Maitland, M. L., Desai, A. A., Singleton, P. A., Sammani, S., Sam, L., Liu, Y., Husain, A. N., Lang, R. M., Ratain, M. J., Lussier, Y. A., Garcia, J. G. N. (2008). Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol. Genomics 33: 278-291 [Abstract] [Full Text]  
• Waxman, J., Kenny, L., Ngan, S. (2008). New treatments for kidney cancer. BMJ 336: 681-682 [Full Text]  
• Dang, D. T., Chun, S. Y., Burkitt, K., Abe, M., Chen, S., Havre, P., Mabjeesh, N. J., Heath, E. I., Vogelzang, N. J., Cruz-Correa, M., Blayney, D. W., Ensminger, W. D., Croix, B. St., Dang, N. H., Dang, L. H. (2008). Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition. Cancer Res. 68: 1872-1880 [Abstract] [Full Text]  
• Gautschi, O., Heighway, J., Mack, P. C., Purnell, P. R., Lara, P. N. Jr., Gandara, D. R. (2008). Aurora Kinases as Anticancer Drug Targets. Clin. Cancer Res. 14: 1639-1648 [Abstract] [Full Text]  
• Daugherty, C. K., Ratain, M. J., Emanuel, E. J., Farrell, A. T., Schilsky, R. L. (2008). Ethical, Scientific, and Regulatory Perspectives Regarding the Use of Placebos in Cancer Clinical Trials. JCO 26: 1371-1378 [Abstract] [Full Text]  
• Williams, L R, Oldale, M J, Bradley, A J (2008). Imaging renal masses and staging renal tumours. Imaging 20: 73-86 [Abstract] [Full Text]  
• Ocana, A., Pandiella, A. (2008). Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options. Clin. Cancer Res. 14: 961-970 [Abstract] [Full Text]  
• Tamaskar, I., Bukowski, R., Elson, P., Ioachimescu, A. G., Wood, L., Dreicer, R., Mekhail, T., Garcia, J., Rini, B. I. (2008). Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol 19: 265-268 [Abstract] [Full Text]  
• Hiles, J. J., Kolesar, J. M. (2008). Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65: 123-131 [Abstract] [Full Text]  
• Grothey, A., Hedrick, E. E., Mass, R. D., Sarkar, S., Suzuki, S., Ramanathan, R. K., Hurwitz, H. I., Goldberg, R. M., Sargent, D. J. (2008). Response-Independent Survival Benefit in Metastatic Colorectal Cancer: A Comparative Analysis of N9741 and AVF2107. JCO 26: 183-189 [Abstract] [Full Text]  
• Choueiri, T. K., Plantade, A., Elson, P., Negrier, S., Ravaud, A., Oudard, S., Zhou, M., Rini, B. I., Bukowski, R. M., Escudier, B. (2008). Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma. JCO 26: 127-131 [Abstract] [Full Text]  
• Stadler, W. M. (2008). Tumor Burden Endpoints and Phase II Clinical Trial Design. Am Soc Clin Oncol Ed Book 2008: 89-93 [Abstract] [Full Text]  
• Schlom, J., Arlen, P. M., Gulley, J. L. (2008). Immunotherapies with Other Therapeutic Modalities: New Paradigms for Clinical Trial Design. Am Soc Clin Oncol Ed Book 2008: 101-106 [Abstract] [Full Text]  
• Rathmell, W. K., Stadler, W. M., Rini, B. I. (2008). Rational Therapeutic Choices and Strategies for Patients with Metastatic Renal Cancer. Am Soc Clin Oncol Ed Book 2008: 192-198 [Abstract] [Full Text]  
• Sourbier, C., Danilin, S., Lindner, V., Steger, J., Rothhut, S., Meyer, N., Jacqmin, D., Helwig, J.-J., Lang, H., Massfelder, T. (2007). Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy. Cancer Res. 67: 11668-11676 [Abstract] [Full Text]  
• Rixe, O., Fojo, T. (2007). Is Cell Death a Critical End Point for Anticancer Therapies or Is Cytostasis Sufficient?. Clin. Cancer Res. 13: 7280-7287 [Abstract] [Full Text]  
• Costa, L. J., Drabkin, H. A. (2007). Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies. The Oncologist 12: 1404-1415 [Abstract] [Full Text]  
• Widakowich, C., de Castro, G. Jr., de Azambuja, E., Dinh, P., Awada, A. (2007). Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. The Oncologist 12: 1443-1455 [Abstract] [Full Text]  
• Ratain, M. J., Glassman, R. H. (2007). Biomarkers in Phase I Oncology Trials: Signal, Noise, or Expensive Distraction?. Clin. Cancer Res. 13: 6545-6548 [Full Text]  
• Ebbinghaus, S., Hussain, M., Tannir, N., Gordon, M., Desai, A. A., Knight, R. A., Humerickhouse, R. A., Qian, J., Gordon, G. B., Figlin, R. (2007). Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma. Clin. Cancer Res. 13: 6689-6695 [Abstract] [Full Text]  
• Akaza, H., Tsukamoto, T., Murai, M., Nakajima, K., Naito, S. (2007). Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma. Jpn J Clin Oncol 0: hym095v1-8 [Abstract] [Full Text]  
• Harrison, M. L., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles, K., Ahern, R., King, D. M., Eisen, T., Corringham, R., DeWitte, M., Balkwill, F., Gore, M. (2007). Tumor Necrosis Factor {alpha} As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose. JCO 25: 4542-4549 [Abstract] [Full Text]  
• Karrison, T. G., Maitland, M. L., Stadler, W. M., Ratain, M. J. (2007). Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer. JNCI J Natl Cancer Inst 99: 1455-1461 [Abstract] [Full Text]  
• Morikawa, T., Sugiyama, A., Kume, H., Ota, S., Kashima, T., Tomita, K., Kitamura, T., Kodama, T., Fukayama, M., Aburatani, H. (2007). Identification of Toll-Like Receptor 3 as a Potential Therapeutic Target in Clear Cell Renal Cell Carcinoma. Clin. Cancer Res. 13: 5703-5709 [Abstract] [Full Text]  
• Klement, H., St. Croix, B., Milsom, C., May, L., Guo, Q., Yu, J. L., Klement, P., Rak, J. (2007). Atherosclerosis and Vascular Aging as Modifiers of Tumor Progression, Angiogenesis, and Responsiveness to Therapy. Am. J. Pathol. 171: 1342-1351 [Abstract] [Full Text]  
• Kwak, E. L., Clark, J. W., Chabner, B. (2007). Targeted Agents: The Rules of Combination. Clin. Cancer Res. 13: 5232-5237 [Abstract] [Full Text]  
• Duda, D. G., Jain, R. K., Willett, C. G. (2007). Antiangiogenics: The Potential Role of Integrating This Novel Treatment Modality With Chemoradiation for Solid Cancers. JCO 25: 4033-4042 [Abstract] [Full Text]  
• Duran, I., Hotte, S. J., Hirte, H., Chen, E. X., MacLean, M., Turner, S., Duan, L., Pond, G. R., Lathia, C., Walsh, S., Wright, J. J., Dancey, J., Siu, L. L. (2007). Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors. Clin. Cancer Res. 13: 4849-4857 [Abstract] [Full Text]  
• Gollob, J. A., Rathmell, W. K., Richmond, T. M., Marino, C. B., Miller, E. K., Grigson, G., Watkins, C., Gu, L., Peterson, B. L., Wright, J. J. (2007). Phase II Trial of Sorafenib Plus Interferon Alfa-2b As First- or Second-Line Therapy in Patients With Metastatic Renal Cell Cancer. JCO 25: 3288-3295 [Abstract] [Full Text]  
• Ryan, C. W., Goldman, B. H., Lara, P. N. Jr, Mack, P. C., Beer, T. M., Tangen, C. M., Lemmon, D., Pan, C.-X., Drabkin, H. A., Crawford, E. D. (2007). Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group. JCO 25: 3296-3301 [Abstract] [Full Text]  
• Izzedine, H., Brocheriou, I., Rixe, O., Deray, G. (2007). Interstitial nephritis in a patient taking sorafenib. Nephrol Dial Transplant 22: 2411-2411 [Full Text]  
• Shaked, Y., Kerbel, R. S. (2007). Antiangiogenic Strategies on Defense: On the Possibility of Blocking Rebounds by the Tumor Vasculature after Chemotherapy. Cancer Res. 67: 7055-7058 [Abstract] [Full Text]  
• van Heeckeren, W. J., Ortiz, J., Cooney, M. M., Remick, S. C. (2007). Hypertension, Proteinuria, and Antagonism of Vascular Endothelial Growth Factor Signaling: Clinical Toxicity, Therapeutic Target, or Novel Biomarker?. JCO 25: 2993-2995 [Full Text]  
• Stein, M. N., Flaherty, K. T. (2007). CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma. Clin. Cancer Res. 13: 3765-3770 [Full Text]  
• Schlom, J., Arlen, P. M., Gulley, J. L. (2007). Cancer Vaccines: Moving Beyond Current Paradigms. Clin. Cancer Res. 13: 3776-3782 [Abstract] [Full Text]